TITLE:
Alternate-Day Buprenorphine Administration. Phase IV - 5

CONDITION:
Opioid-Related Disorders

INTERVENTION:
Buprenorphine

SUMMARY:

      The purpose of this study is to determine if three times a subject's daily maintenance dose
      will hold for 72 hours without changes in agonist and antagonist effects.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 20 Years to 49 Years
Criteria:

        Please contact site for information.
      
